The past decades have witnessed a rapid development in the pediatric field along with the development of medical sciences in China. However, the increasing demand for pediatric healthcare services still cannot be met owing to various reasons. The shortage of pediatric medical resources and the limited access to medical care for pediatric patients have long been the priorities of healthcare reform in China.
In May 2013, the Beijing Children's Hospital, Capital Medical University, led the establishment of the National Pediatric Medical Union-Beijing Children's Hospital Group. In August 2016, the Ministry of Civil Affairs of the People's Republic of China further approved the establishment of the Futang Research Center of Pediatric Development (FRCPD). With the joint efforts of 26 provincial tertiary children's hospitals, a cross-regional pediatric diagnostic and treatment service network covering 24 provinces, municipalities, and autonomous regions has recently been formed. This network has enabled the establishment of a four-level pediatric medical service system, with the National Center for Children's Health (Beijing) as the core center, and there are more than 1800 primary medical institutions as its members. The FRCPD intends to further integrate premium pediatric resources and gradually equalize the quality of medical care through sharing of medical treatment, teaching, scientific research, prevention, experts, and management. It also makes an effort in building a hierarchical medical care system that enables first diagnosis at grassroots clinics, two-way referral, triage of chronic and acute diseases, and cross-level connection, as well as the adoption of the "doctors go to see patients" model.
With an attempt to promote the advances in pediatrics, the FRCPD and the Science China-Life Sciences jointly launched this special topic of Futang pediatrics. Most authors of this issue are middle-aged pediatricians from seven member institutions of the FRCPD, including Xi'an Children's Hospital, Anhui Provincial Children's Hospital, Children's Hospital of Nanjing Medical University, Jinan Children's Hospital, Wuhan Children's Hospital, Hunan Children's Hospital, Hebei Provincial Children's Hospital, and Beijing Children's Hospital, Capital Medical University. Despite their busy schedule, these authors keep abreast of the latest scientific and technological developments in pediatrics by focusing on basic and clinical research on the etiology, diagnosis, and treatment of various childhood diseases. We give special thanks to Drs. Guo Yongli, and Xu Zhifei as well as all the managing editors who have helped solicit manuscripts and write articles in English.
With the increased recognition of children's healthcare by the Chinese Government and society, progress in the new healthcare reform, and the release of a series of policies, pediatrics in China is embracing a new future. The FRCPD is the first nonprofit social welfare organization that is committed to the development of pediatric medicine in China. This center will conduct win-win, open, and transparent cooperation with pediatric medical staff, promote the research and application of new pediatric diagnostic and treatment technologies, and establish training platforms for all healthcare providers in this field. By integrating all the premium pediatric resources, this center wishes to work with pediatricians and all other stakeholders nationwide to further promote and optimize children's healthcare in China.
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